Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Sold by Vanguard Capital Wealth Advisors

Vanguard Capital Wealth Advisors trimmed its position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Free Report) by 21.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 59,000 shares of the company’s stock after selling 16,500 shares during the quarter. Vanguard Capital Wealth Advisors’ holdings […]

Related Keywords

,Nasdaq ,Jpmorgan Chase Co ,Morgan Stanley ,Exchange Commission ,Geode Capital Management ,Nautilus Biotechnology Inc ,Deutsche Bank ,Vanguard Capital Wealth Advisors ,Nautilus Biotechnology ,Free Report ,Capital Wealth Advisor ,Street Group ,Street Corp ,Capital Management ,Biotechnology Trading Down ,Get Free Report ,Nautilus Platform ,Nautilus Biotechnology Daily ,Nasdaq Naut ,Ranaut ,Medical ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,